Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 41

1.

Simultaneous Targeting of DNA Replication and Homologous Recombination in Glioblastoma with a Polyether Ionophore.

Lim YC, Ensbey KS, Offenhäuser C, D'Souza RCJ, Cullen JK, Stringer BW, Quek H, Bruce ZC, Kijas A, Cianfanelli V, Mahboubi B, Smith F, Jeffree RL, Wiesmüeller L, Wiegmans AP, Bain A, Lombard FJ, Roberts TL, Khanna KK, Lavin MF, Baek K, Hamerlik P, Johns TG, Coster MJ, Boyd AW, Day BW.

Neuro Oncol. 2019 Aug 30. pii: noz159. doi: 10.1093/neuonc/noz159. [Epub ahead of print]

PMID:
31504812
2.

The dystroglycan receptor maintains glioma stem cells in the vascular niche.

Day BW, Lathia JD, Bruce ZC, D'Souza RCJ, Baumgartner U, Ensbey KS, Lim YC, Stringer BW, Akgül S, Offenhäuser C, Li Y, Jamieson PR, Smith FM, Jurd CLR, Robertson T, Inglis PL, Lwin Z, Jeffree RL, Johns TG, Bhat KPL, Rich JN, Campbell KP, Boyd AW.

Acta Neuropathol. 2019 Aug 28. doi: 10.1007/s00401-019-02069-x. [Epub ahead of print]

PMID:
31463571
3.

A reference collection of patient-derived cell line and xenograft models of proneural, classical and mesenchymal glioblastoma.

Stringer BW, Day BW, D'Souza RCJ, Jamieson PR, Ensbey KS, Bruce ZC, Lim YC, Goasdoué K, Offenhäuser C, Akgül S, Allan S, Robertson T, Lucas P, Tollesson G, Campbell S, Winter C, Do H, Dobrovic A, Inglis PL, Jeffree RL, Johns TG, Boyd AW.

Sci Rep. 2019 Mar 20;9(1):4902. doi: 10.1038/s41598-019-41277-z.

4.

Expression and activity of the calcitonin receptor family in a sample of primary human high-grade gliomas.

Ostrovskaya A, Hick C, Hutchinson DS, Stringer BW, Wookey PJ, Wootten D, Sexton PM, Furness SGB.

BMC Cancer. 2019 Feb 18;19(1):157. doi: 10.1186/s12885-019-5369-y.

5.

Intratumoural Heterogeneity Underlies Distinct Therapy Responses and Treatment Resistance in Glioblastoma.

Akgül S, Patch AM, D'Souza RCJ, Mukhopadhyay P, Nones K, Kempe S, Kazakoff SH, Jeffree RL, Stringer BW, Pearson JV, Waddell N, Day BW.

Cancers (Basel). 2019 Feb 6;11(2). pii: E190. doi: 10.3390/cancers11020190.

6.

Novel dual-action prodrug triggers apoptosis in glioblastoma cells by releasing a glutathione quencher and lysine-specific histone demethylase 1A inhibitor.

Engel M, Gee YS, Cross D, Maccarone A, Heng B, Hulme A, Smith G, Guillemin GJ, Stringer BW, Hyland CJT, Ooi L.

J Neurochem. 2019 May;149(4):535-550. doi: 10.1111/jnc.14655. Epub 2019 Feb 3.

7.

EphA3 Pay-Loaded Antibody Therapeutics for the Treatment of Glioblastoma.

Offenhäuser C, Al-Ejeh F, Puttick S, Ensbey KS, Bruce ZC, Jamieson PR, Smith FM, Stringer BW, Carrington B, Fuchs AV, Bell CA, Jeffree R, Rose S, Thurecht KJ, Boyd AW, Day BW.

Cancers (Basel). 2018 Dec 17;10(12). pii: E519. doi: 10.3390/cancers10120519.

8.

Extracellular Vesicles Released by Glioblastoma Cells Stimulate Normal Astrocytes to Acquire a Tumor-Supportive Phenotype Via p53 and MYC Signaling Pathways.

Hallal S, Mallawaaratchy DM, Wei H, Ebrahimkhani S, Stringer BW, Day BW, Boyd AW, Guillemin GJ, Buckland ME, Kaufman KL.

Mol Neurobiol. 2019 Jun;56(6):4566-4581. doi: 10.1007/s12035-018-1385-1. Epub 2018 Oct 23.

9.

Cytoplasmic dynein regulates the subcellular localization of sphingosine kinase 2 to elicit tumor-suppressive functions in glioblastoma.

Neubauer HA, Tea MN, Zebol JR, Gliddon BL, Stefanidis C, Moretti PAB, Pitman MR, Costabile M, Kular J, Stringer BW, Day BW, Samuel MS, Bonder CS, Powell JA, Pitson SM.

Oncogene. 2019 Feb;38(8):1151-1165. doi: 10.1038/s41388-018-0504-9. Epub 2018 Sep 24.

10.

Changes in cell morphology guide identification of tubulin as the off-target for protein kinase inhibitors.

Hoque M, Abbassi RH, Froio D, Man J, Johns TG, Stringer BW, Day BW, Pajic M, Kassiou M, Munoz L.

Pharmacol Res. 2018 Aug;134:166-178. doi: 10.1016/j.phrs.2018.06.023. Epub 2018 Jun 23.

PMID:
29944980
11.

A unique 19F MRI agent for the tracking of non phagocytic cells in vivo.

Moonshi SS, Zhang C, Peng H, Puttick S, Rose S, Fisk NM, Bhakoo K, Stringer BW, Qiao GG, Gurr PA, Whittaker AK.

Nanoscale. 2018 May 3;10(17):8226-8239. doi: 10.1039/c8nr00703a.

PMID:
29682654
12.

Cyclin-dependent kinase 7 is a therapeutic target in high-grade glioma.

Greenall SA, Lim YC, Mitchell CB, Ensbey KS, Stringer BW, Wilding AL, O'Neill GM, McDonald KL, Gough DJ, Day BW, Johns TG.

Oncogenesis. 2017 May 15;6(5):e336. doi: 10.1038/oncsis.2017.33.

13.

Dianthin-30 or gelonin versus monomethyl auristatin E, each configured with an anti-calcitonin receptor antibody, are differentially potent in vitro in high-grade glioma cell lines derived from glioblastoma.

Gilabert-Oriol R, Furness SGB, Stringer BW, Weng A, Fuchs H, Day BW, Kourakis A, Boyd AW, Hare DL, Thakur M, Johns TG, Wookey PJ.

Cancer Immunol Immunother. 2017 Sep;66(9):1217-1228. doi: 10.1007/s00262-017-2013-z. Epub 2017 May 13.

PMID:
28501939
14.

Development and Biological Evaluation of a Photoactivatable Small Molecule Microtubule-Targeting Agent.

Döbber A, Phoa AF, Abbassi RH, Stringer BW, Day BW, Johns TG, Abadleh M, Peifer C, Munoz L.

ACS Med Chem Lett. 2017 Mar 15;8(4):395-400. doi: 10.1021/acsmedchemlett.6b00483. eCollection 2017 Apr 13.

15.

Structural Optimization and Pharmacological Evaluation of Inhibitors Targeting Dual-Specificity Tyrosine Phosphorylation-Regulated Kinases (DYRK) and CDC-like kinases (CLK) in Glioblastoma.

Zhou Q, Phoa AF, Abbassi RH, Hoque M, Reekie TA, Font JS, Ryan RM, Stringer BW, Day BW, Johns TG, Munoz L, Kassiou M.

J Med Chem. 2017 Mar 9;60(5):2052-2070. doi: 10.1021/acs.jmedchem.6b01840. Epub 2017 Feb 28.

PMID:
28206758
16.

Anti-GD2-ch14.18/CHO coated nanoparticles mediate glioblastoma (GBM)-specific delivery of the aromatase inhibitor, Letrozole, reducing proliferation, migration and chemoresistance in patient-derived GBM tumor cells.

Tivnan A, Heilinger T, Ramsey JM, O'Connor G, Pokorny JL, Sarkaria JN, Stringer BW, Day BW, Boyd AW, Kim EL, Lode HN, Cryan SA, Prehn JH.

Oncotarget. 2017 Mar 7;8(10):16605-16620. doi: 10.18632/oncotarget.15073.

17.

EphA3 as a target for antibody immunotherapy in acute lymphoblastic leukemia.

Charmsaz S, Al-Ejeh F, Yeadon TM, Miller KJ, Smith FM, Stringer BW, Moore AS, Lee FT, Cooper LT, Stylianou C, Yarranton GT, Woronicz J, Scott AM, Lackmann M, Boyd AW.

Leukemia. 2017 Aug;31(8):1779-1787. doi: 10.1038/leu.2016.371. Epub 2016 Dec 6.

PMID:
27922598
18.

Nuclear factor one B (NFIB) encodes a subtype-specific tumour suppressor in glioblastoma.

Stringer BW, Bunt J, Day BW, Barry G, Jamieson PR, Ensbey KS, Bruce ZC, Goasdoué K, Vidal H, Charmsaz S, Smith FM, Cooper LT, Piper M, Boyd AW, Richards LJ.

Oncotarget. 2016 May 17;7(20):29306-20. doi: 10.18632/oncotarget.8720.

19.

Differential response of patient-derived primary glioblastoma cells to environmental stiffness.

Grundy TJ, De Leon E, Griffin KR, Stringer BW, Day BW, Fabry B, Cooper-White J, O'Neill GM.

Sci Rep. 2016 Mar 21;6:23353. doi: 10.1038/srep23353.

20.

Patient-derived glioblastoma cells show significant heterogeneity in treatment responses to the inhibitor-of-apoptosis-protein antagonist birinapant.

Zakaria Z, Tivnan A, Flanagan L, Murray DW, Salvucci M, Stringer BW, Day BW, Boyd AW, Kögel D, Rehm M, O'Brien DF, Byrne AT, Prehn JH.

Br J Cancer. 2016 Jan 19;114(2):188-98. doi: 10.1038/bjc.2015.420. Epub 2015 Dec 10.

21.

Pharmacology of novel small-molecule tubulin inhibitors in glioblastoma cells with enhanced EGFR signalling.

Phoa AF, Browne S, Gurgis FM, Åkerfeldt MC, Döbber A, Renn C, Peifer C, Stringer BW, Day BW, Wong C, Chircop M, Johns TG, Kassiou M, Munoz L.

Biochem Pharmacol. 2015 Dec 15;98(4):587-601. doi: 10.1016/j.bcp.2015.10.014. Epub 2015 Oct 28.

PMID:
26519552
22.

EphA2 as a Diagnostic Imaging Target in Glioblastoma: A Positron Emission Tomography/Magnetic Resonance Imaging Study.

Puttick S, Stringer BW, Day BW, Bruce ZC, Ensbey KS, Mardon K, Cowin GJ, Thurecht KJ, Whittaker AK, Fay M, Boyd AW, Rose S.

Mol Imaging. 2015;14:385-99.

PMID:
26218510
23.

Neurosphere and adherent culture conditions are equivalent for malignant glioma stem cell lines.

Rahman M, Reyner K, Deleyrolle L, Millette S, Azari H, Day BW, Stringer BW, Boyd AW, Johns TG, Blot V, Duggal R, Reynolds BA.

Anat Cell Biol. 2015 Mar;48(1):25-35. doi: 10.5115/acb.2015.48.1.25. Epub 2015 Mar 20.

24.

Eph family co-expression patterns define unique clusters predictive of cancer phenotype.

Al-Ejeh F, Offenhäuser C, Lim YC, Stringer BW, Day BW, Boyd AW.

Growth Factors. 2014 Dec;32(6):254-64. doi: 10.3109/08977194.2014.984807. Epub 2014 Nov 20. Review.

PMID:
25410964
25.

Eph receptors as therapeutic targets in glioblastoma.

Day BW, Stringer BW, Boyd AW.

Br J Cancer. 2014 Sep 23;111(7):1255-61. doi: 10.1038/bjc.2014.73. Epub 2014 Aug 21. Review.

26.

Increased sensitivity to ionizing radiation by targeting the homologous recombination pathway in glioma initiating cells.

Lim YC, Roberts TL, Day BW, Stringer BW, Kozlov S, Fazry S, Bruce ZC, Ensbey KS, Walker DG, Boyd AW, Lavin MF.

Mol Oncol. 2014 Dec;8(8):1603-15. doi: 10.1016/j.molonc.2014.06.012. Epub 2014 Jun 27.

27.

NFIB-mediated repression of the epigenetic factor Ezh2 regulates cortical development.

Piper M, Barry G, Harvey TJ, McLeay R, Smith AG, Harris L, Mason S, Stringer BW, Day BW, Wray NR, Gronostajski RM, Bailey TL, Boyd AW, Richards LJ.

J Neurosci. 2014 Feb 19;34(8):2921-30. doi: 10.1523/JNEUROSCI.2319-13.2014.

28.

A metabolic shift favoring sphingosine 1-phosphate at the expense of ceramide controls glioblastoma angiogenesis.

Abuhusain HJ, Matin A, Qiao Q, Shen H, Kain N, Day BW, Stringer BW, Daniels B, Laaksonen MA, Teo C, McDonald KL, Don AS.

J Biol Chem. 2013 Dec 27;288(52):37355-64. doi: 10.1074/jbc.M113.494740. Epub 2013 Nov 21.

29.

Glioma surgical aspirate: a viable source of tumor tissue for experimental research.

Day BW, Stringer BW, Wilson J, Jeffree RL, Jamieson PR, Ensbey KS, Bruce ZC, Inglis P, Allan S, Winter C, Tollesson G, Campbell S, Lucas P, Findlay W, Kadrian D, Johnson D, Robertson T, Johns TG, Bartlett PF, Osborne GW, Boyd AW.

Cancers (Basel). 2013 Apr 3;5(2):357-71. doi: 10.3390/cancers5020357.

30.

The tumor suppressor microRNA, miR-124a, is regulated by epigenetic silencing and by the transcriptional factor, REST in glioblastoma.

Tivnan A, Zhao J, Johns TG, Day BW, Stringer BW, Boyd AW, Tiwari S, Giles KM, Teo C, McDonald KL.

Tumour Biol. 2014 Feb;35(2):1459-65. doi: 10.1007/s13277-013-1200-6. Epub 2013 Sep 26.

PMID:
24068568
31.

Brain tumor initiating cells adapt to restricted nutrition through preferential glucose uptake.

Flavahan WA, Wu Q, Hitomi M, Rahim N, Kim Y, Sloan AE, Weil RJ, Nakano I, Sarkaria JN, Stringer BW, Day BW, Li M, Lathia JD, Rich JN, Hjelmeland AB.

Nat Neurosci. 2013 Oct;16(10):1373-82. doi: 10.1038/nn.3510. Epub 2013 Sep 1.

32.

The transcription factor C/EBP-β mediates constitutive and LPS-inducible transcription of murine SerpinB2.

Udofa EA, Stringer BW, Gade P, Mahony D, Buzza MS, Kalvakolanu DV, Antalis TM.

PLoS One. 2013;8(3):e57855. doi: 10.1371/journal.pone.0057855. Epub 2013 Mar 5.

33.

EphA3 maintains tumorigenicity and is a therapeutic target in glioblastoma multiforme.

Day BW, Stringer BW, Al-Ejeh F, Ting MJ, Wilson J, Ensbey KS, Jamieson PR, Bruce ZC, Lim YC, Offenhäuser C, Charmsaz S, Cooper LT, Ellacott JK, Harding A, Leveque L, Inglis P, Allan S, Walker DG, Lackmann M, Osborne G, Khanna KK, Reynolds BA, Lickliter JD, Boyd AW.

Cancer Cell. 2013 Feb 11;23(2):238-48. doi: 10.1016/j.ccr.2013.01.007.

34.

ELK4 neutralization sensitizes glioblastoma to apoptosis through downregulation of the anti-apoptotic protein Mcl-1.

Day BW, Stringer BW, Spanevello MD, Charmsaz S, Jamieson PR, Ensbey KS, Carter JC, Cox JM, Ellis VJ, Brown CL, Walker DG, Inglis PL, Allan S, Reynolds BA, Lickliter JD, Boyd AW.

Neuro Oncol. 2011 Nov;13(11):1202-12. doi: 10.1093/neuonc/nor119. Epub 2011 Aug 16.

35.

Ephrin expression and function in cancer.

McCarron JK, Stringer BW, Day BW, Boyd AW.

Future Oncol. 2010 Jan;6(1):165-76. doi: 10.2217/fon.09.146. Review.

PMID:
20021216
36.

The glycosylphosphatidylinositol-anchored serine protease PRSS21 (testisin) imparts murine epididymal sperm cell maturation and fertilizing ability.

Netzel-Arnett S, Bugge TH, Hess RA, Carnes K, Stringer BW, Scarman AL, Hooper JD, Tonks ID, Kay GF, Antalis TM.

Biol Reprod. 2009 Nov;81(5):921-32. doi: 10.1095/biolreprod.109.076273. Epub 2009 Jul 1.

37.

Serum and wound drain ropivacaine concentrations after wound infiltration in joint arthroplasty.

Stringer BW, Singhania AK, Sudhakar JE, Brink RB.

J Arthroplasty. 2007 Sep;22(6):884-92. Epub 2007 Jul 25.

PMID:
17826281
38.

Inhibition of retinoblastoma protein degradation by interaction with the serpin plasminogen activator inhibitor 2 via a novel consensus motif.

Darnell GA, Antalis TM, Johnstone RW, Stringer BW, Ogbourne SM, Harrich D, Suhrbier A.

Mol Cell Biol. 2003 Sep;23(18):6520-32.

40.
41.

Scavenging adaptor misconnection.

Stringer BW.

Anaesth Intensive Care. 1982 May;10(2):169. No abstract available.

PMID:
7103049

Supplemental Content

Loading ...
Support Center